established a novel IGF2BP1/CDC5L pathogenic axis in multiple myeloma (MM), where BTYNB effectively suppresses the expression of CDC5L, thereby inhibiting MM progression (206). The gene discussed is CDC5L; the disease is AL amyloidosis.